Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast its
presentation at the Leerink Swann Novel Cancer Therapeutics Roundtable
Conference on Wednesday, May 20, 2009. The presentation, which is
scheduled for 11:00 a.m. Eastern Time, will provide a brief overview of
the Company and include a question-and-answer session with a Leerink
Swann analyst. The session may be accessed through the Company’s web
site, www.regeneron.com,
on the Investor Relations page under the Presentations heading. An
archived version of the presentation will be available after the live
webcast through June 19, 2009. Additional information about Regeneron
and recent news releases are available on the Regeneron web site.
Regeneron is a fully integrated biopharmaceutical company that
discovers, develops, and commercializes medicines for the treatment of
serious medical conditions. In addition to ARCALYST®
(rilonacept) Injection for Subcutaneous Use, its first commercialized
product, Regeneron has therapeutic candidates in clinical trials for the
potential treatment of cancer, eye diseases, inflammatory diseases, and
pain, and has preclinical programs in other diseases and disorders.
Regeneron Pharmaceuticals, Inc.
Investor Relations
Peter
Dworkin, 914-345-7640
peter.dworkin@regeneron.com
or
Media
Relations
Laura Lindsay, 914-345-7800
laura.lindsay@regeneron.com
or
Olga
Fleming, 212-845-5636
ofleming@biosector2.com
